TGFB1 and neoplasm: In subcutaneous tumor-bearing mice, combined treatment of EcN and TGF-β blockers has been shown to be superior to monotherapy, and this synergy is probably mediated by the interaction of tumor-specific effector T cells, antigen-specific IFN-γ+ CD8+ T cells, and the gut microbiota [47].